**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process.**
New Approaches to Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation is a potentially curative therapeutic option for all hematologic malignancies. It is a double-edged sword that may result in significant mortality and morbidity. In recent years, there are ground-breaking advances in more availability of stem cell sources, emerging strategies for choosing the best donor, graft versus host disease (GVHD) prevention and treatment strategies as well as supportive care. Ultra-high resolution (UHR) using next-generation sequencing technology has been introduced to get more information that is sensitive on HLA typing possible to access the best-matched donors. Functional HLA matching with TCE3 and TCE4 and a scoring system named by “delta functional distance” (ΔFD) may help to GVL-GVHD counterbalance to the GVL direction. More effective GVHD prophylaxis (post-transplant cyclophosphamide and ATG) make it possible to reach broader donor diversity in terms of unrelated and haploidentical setting. Ex-vivo stem cell expansion with numerous small molecules (stem regenin 1, TAT-BMI1, nicotinamide, valproic acid) can improve engraftment and immune reconstitution rates in UCBT. Ruxolitinib, ibrutinib, vedolizumab, alpha-1 antitrypsin (AAT) and, mesenchymal stromal cells have promising results in the treatment of acute and chronic GVHD settings. Letermovir and maribavir have also encouraging results in CMV reactivation prophylaxis. This article summarizes the current state of art and paradigm shifts in allo-HCT.
Allogeneic hematopoietic cell transplantation, GVHD, HLA typing, conditioning regimen, stem cell source
Cemaleddin Ozturk and Sinem Civriz Bozdag have no financial or non-financial relationships or activities to declare in relation to this article.
Compliance With Ethics
This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.
Double-blind peer review.
Both named authors meet the criteria of the International Committee of Medical Journal Editors (ICMJE) for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.
Cemaleddin Ozturk, MD, Department of Hematology Ankara University, Balkiraz Mah. Mamak Cd. No:12, 06620 Mamak/Ankara TURKEY
No funding was received in the publication of this article.
This article is freely accessible at touchONCOLOGY.com © Touch Medical Media 2020.
Share this Article
Related Content In Haematology
Sutimlimab for the Treatment of Cold Agglutinin Disease
touchREVIEWS in Oncology & Haematology. 2023;19(1):35-40 DOI: https://doi.org/10.17925/OHR.2023.19.1.35
In recent years, our understanding of the complement system and its role in disease has increased dramatically. With the advent of complement 5 (C5) and C3 inhibitors, our ability to manipulate the complement system has improved the outcomes and quality of life for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic–uraemic syndrome.1–3 More recently, this understanding […]
Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Waldenström’s Macroglobulinaemia: A Canadian Perspective
touchREVIEWS in Oncology & Haematology. 2021;17(2):73–8 DOI: https://doi.org/10.17925/OHR.2021.17.2.73
Current treatment landscape in Canada Waldenström’s macroglobulinaemia (WM) is a rare haematological disorder with an incidence of about three cases per million, leading to approximately 150 new cases per year in Canada.1,2 WM is characterized by a clonal lymphoplasmacytic infiltration of the bone marrow and the presence of an IgM monoclonal protein.3,4 Symptomatic disease can arise from […]
Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria
touchREVIEWS in Oncology & Haematology. 2021;17(2):84–9 DOI: https://doi.org/10.17925/OHR.2021.17.2.84
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, chronic haematological illness. The condition presents on a background of bone marrow failure, and affected individuals can experience an array of symptoms due to chronic haemolysis, as well as episodes of acute haemolysis and thrombotic events.1 Diagnostic delays in PNH are common as not all patients experience classical symptoms, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!